We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $524M
1-Year Est. Return 164.42%
This Fund
S&P 500
This Quarter Est. Return
+25.66%
1 Year Est. Return
+164.42%
3 Year Est. Return
+313.04%
5 Year Est. Return
+302.83%
10 Year Est. Return
+4,361.99%
AUM
$431M
AUM Growth
+$25.7M
Cap. Flow
-$49.3M
Cap. Flow %
-11.46%
Top 10 Hldgs %
54.85%
Holding
87
New
12
Increased
16
Reduced
29
Closed
10

Top Buys

Rank Stock Value
1
BHVN icon
Biohaven
BHVN
+$8.92M
2
PRCT icon
Procept Biorobotics
PRCT
+$3.98M
3
HELP
Cybin Inc
HELP
+$2.93M
4
DNLI icon
Denali Therapeutics
DNLI
+$2.53M
5
MPLT
MapLight Therapeutics
MPLT
+$2.41M

Top Sells

Rank Stock Value
1
MRUS
Merus
MRUS
+$20.8M
2
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$7.45M
3
AXGN icon
Axogen
AXGN
+$6.53M
4
IBB icon
iShares Biotechnology ETF
IBB
+$5.59M
5
RCUS icon
Arcus Biosciences
RCUS
+$4M

Sector Composition

Rank Sector Weight
1 Healthcare 86.53%
2 Miscellaneous 13.47%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RVMD icon
1
Revolution Medicines
RVMD
$44.6B
$48.1M 11.18%
604,514
-52,662
-8% -$3.45M
XBI icon
2
State Street SPDR S&P Biotech ETF
XBI
$11.3B
$41M 9.53%
336,505
-65,000
-16% -$7.45M
STXS icon
3
Stereotaxis
STXS
$145M
$31.5M 7.31%
13,680,554
– –
ATRC icon
4
AtriCure
ATRC
$2.47B
$23.6M 5.49%
597,431
+5,158
+0.9% +$189K
CYTK icon
5
Cytokinetics
CYTK
$10B
$23.6M 5.48%
370,997
-23,943
-6% -$1.49M
IDYA icon
6
IDEAYA Biosciences
IDYA
$3.87B
$17.5M 4.07%
506,740
-33,183
-6% -$1.06M
AXGN icon
7
Axogen
AXGN
$2.77B
$15.6M 3.63%
476,826
-265,456
-36% -$6.53M
XENE icon
8
Xenon Pharmaceuticals
XENE
$5.81B
$12.9M 3%
287,939
– –
IBB icon
9
iShares Biotechnology ETF
IBB
$10.5B
$11.5M 2.67%
68,095
-34,405
-34% -$5.59M
BHVN icon
10
Biohaven
BHVN
$2.33B
$10.8M 2.51%
955,235
+720,000
+306% +$8.92M
RCUS icon
11
Arcus Biosciences
RCUS
$3.72B
$10.3M 2.39%
431,329
-196,297
-31% -$4M
NBIX icon
12
Neurocrine Biosciences
NBIX
$15.7B
$10M 2.33%
70,615
– –
DAWN
13
DELISTED
Day One Biopharmaceuticals
DAWN
$9.31M 2.16%
999,163
– –
TNDM icon
14
Tandem Diabetes Care
TNDM
$1.49B
$7.81M 1.81%
355,208
– –
ASND icon
15
Ascendis Pharma A/S
ASND
$16.3B
$6.01M 1.4%
28,177
-5,000
-15% -$1.03M
DXCM icon
16
DexCom
DXCM
$34.3B
$5.86M 1.36%
88,279
+22,727
+35% +$1.47M
SNDX icon
17
Syndax Pharmaceuticals
SNDX
$1.74B
$5.84M 1.36%
277,855
-222,847
-45% -$3.89M
KALV
18
DELISTED
KalVista Pharmaceuticals
KALV
$5.76M 1.34%
356,802
-65,929
-16% -$873K
CMPS
19
Compass Pathways
CMPS
$1.9B
$5.6M 1.3%
811,046
– –
INGN icon
20
Inogen
INGN
$146M
$5.56M 1.29%
827,071
+221,446
+37% +$1.66M
DNLI icon
21
Denali Therapeutics
DNLI
$3.84B
$5.26M 1.22%
318,500
+150,000
+89% +$2.53M
MBX
22
MBX Biosciences
MBX
$3.03B
$5.21M 1.21%
165,265
+80,265
+94% +$1.95M
BCAX
23
Bicara Therapeutics
BCAX
$1.55B
$4.4M 1.02%
261,583
-55,418
-17% -$946K
LKFT
24
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.89B
$4.26M 0.99%
130,175
– –
ATXS
25
DELISTED
Astria Therapeutics
ATXS
$3.99M 0.93%
304,775
-15,000
-5% -$179K
1
2 3 4

Similar funds

4WM
49 Wealth Management Austin, Texas $524M AUM 16.59% 1-Year Est. Return
BB
Berkshire Bank Pittsfield, Massachusetts $524M AUM 21.97% 1-Year Est. Return
A
Alongside Austin, Texas $525M AUM
HW
Hedeker Wealth Lincolnshire, Illinois $524M AUM 36.83% 1-Year Est. Return
DAM
Decagon Asset Management London, United Kingdom $525M AUM 50.51% 1-Year Est. Return
SDWIA
Schwarz Dygos Wheeler Investment Advisors Minneapolis, Minnesota $524M AUM 25.1% 1-Year Est. Return
SCA
Stieven Capital Advisors St. Louis, Missouri $524M AUM 29.72% 1-Year Est. Return
BHPW
Beverly Hills Private Wealth Beverly Hills, California $525M AUM 24.1% 1-Year Est. Return

DAFNA Capital Management's Q4 2025 Portfolio in Review

As of Q4 2025, DAFNA Capital Management held 87 positions worth $431M, up 6.4% from $405M the previous quarter. Its ten largest holdings account for 55% of the portfolio.

DAFNA Capital Management withdrew a net $49.3M in Q4 2025, closing 10 positions and reducing 29 holdings. Its most notable exit was Merus, an estimated $20.8M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 87% of assets, up from 85% a quarter earlier, followed by Miscellaneous.

Against the trend, DAFNA Capital Management opened a new position in Procept Biorobotics worth $3.78M.

  • DAFNA Capital Management's largest Q4 2025 buy was Procept Biorobotics: 120,000 shares worth $3.78M.
  • DAFNA Capital Management added most to Biohaven in Q4 2025, an estimated $8.92M increase.
  • DAFNA Capital Management's biggest Q4 2025 reduction was State Street SPDR S&P Biotech ETF, cutting an estimated $7.45M.
  • DAFNA Capital Management fully exited Merus in Q4 2025, selling an estimated $20.8M.
  • DAFNA Capital Management's ten largest holdings make up 55% of its $431M portfolio in Q4 2025.
  • DAFNA Capital Management opened 12 new positions and closed 10 in Q4 2025.
  • DAFNA Capital Management's portfolio value rose 6.4% quarter-over-quarter to $431M.

Based on DAFNA Capital Management's 13F filing for Q4 2025, filed 17 Feb 2026.